Aim-Helicobacter pylori is associated with gastric cancer. Our aim was to investigate whether CagA or VacA seropositivity provides additional risk for gastric cancer. Methods-Sera from 110 gastric cancer patients were sex and aged matched with asymptomatic controls. H pylori status was determined by IgG enzyme immunoassay (HM-CAP EIA); CagA status was assessed by enzyme linked immunosorbent assay (ELISA) (OraVax) and immunoblotting (Chiron), and VacA status by immunoblotting using recombinant proteins as antigens. Conclusions-H pylori infection causes chronic gastritis and is associated with the development of gastric cancer. Neither CagA nor VacA seropositivity added additional information or stratification. (J Clin Pathol 1999;52:215-218) 
Helicobacter pylori infection is now accepted as the major cause of chronic gastritis. Several epidemiological studies have shown that H pylori infection is also linked to the gastritis associated diseases (gastric cancer and peptic ulcer). [1] [2] [3] In 1994, the International Agency for Research on Cancer categorised H pylori infection as a group I carcinogen. 4 In 1993, an estimated 0.4% of the 60 million Japanese who were infected with H pylori were diagnosed with gastric cancer. 5 6 Thus although gastric cancer is one of the commonest cancers in Japan, only a small percentage of individuals with H pylori infection ever develop it. One possible reason for diVerences in outcome of H pylori infection may relate to diVerences in virulence of H pylori strains.
Studies on bacterial virulence have focused primarily on two groups of putative bacterial virulence factors, the cag pathogenicity island (for which CagA antibody is a marker) and the vacuolating cytotoxin, VacA. Recent serological studies have shown that the CagA and VacA seropositivity were associated with an increased risk of developing atrophic gastritis and gastric cancer. [7] [8] [9] [10] [11] In Japan, the predominant types of H pylori circulating in the population express CagA and VacA. [12] [13] [14] [15] [16] [17] Two recent reports regarding the possible relation of serum anti-CagA antibody in gastric cancer in Japan reached opposite conclusions. 18 19 Katagiri et al reported that there was no relationship between CagA seropositivity and gastric cancer, 18 whereas Shimoyama et al reported the opposite. 19 Both studies used recombinant CagA protein as the antigen for the serological study but the source and structure diVered. Katagiri et al used orv220, a 65 000 fragment CagA protein from OraVax Inc (Cambridge, Massachusetts, USA) whereas Shimoyama et al used a 25 500 fragment antigen from Immunobiological Research Institute Siena (IRIS, Siena, Italy). It is not clear whether their discrepant findings resulted from the use of diVerent populations or diVerent methods, or from diVerences in the antigens used to detect anti-CagA antibodies.
We used both CagA antigens to investigate whether CagA seropositivity was associated with increasing risk of gastric cancer in Japan. We also examined the relation between the VacA seropositivity and gastric cancer using a recombinant VacA antigen.
Methods

PATIENTS
Sera were obtained from 110 Japanese patients with histologically proven gastric cancer (80 men and 30 women, mean age 64.5 years, age range 42 to 84). Early gastric cancer was diagnosed pathologically by the growth of a tumour confined to the mucosa and submucosa of the stomach, as defined by the Japanese Research Society for Gastric Cancer. 20 The histological type of the malignancy was determined according to Lauren, as either intestinal or diVuse type. 21 Two control groups were evaluated. First, each cancer patient was sex and aged matched with asymptomatic control (one control for each case) to assess the role of H pylori infection in gastric cancer (control 1). A second control (control 2) compared CagA antibody and VacA antibody status in H pylori positive cases and required the addition of 29 H pylori antibody positive age and sex matched cases. None of the controls had histology of peptic ulcer disease or dyspepsia. None of the patients had been treated for H pylori, had received recent blood transfusions, non-steroidal antiinflammatory drugs, proton pump inhibitors, or antibiotics within the previous three months.
Informed consent was obtained from all patients and the protocol was approved by the Hospital ethics committee.
Serum samples were stored at −80°C until serological testing. ENZYME IMMUNOASSAY FOR H PYLORI H pylori status was determined by IgG antibodies to H pylori using a commercially available enzyme immunoassay (EIA) kit (HM-CAP EIA, Enteric Products Inc). This assay system is reported to have 98.7% sensitivity and 100% specificity in the United States 22 and 100% sensitivity and 96% specificity in Japan in comparison with the urea breath test. 23 A cutoV optical density of 0.30 was chosen, according to Asaka et al. 23 Furthermore, a sensitivity and specificity of 96% and 98% have been found in 100 dyspeptic patients as determined by culture and histological analysis in our laboratory (data not shown). High titre antibody was defined by an optical density greater than 1.00. ENZYME IMMUNOASSAY FOR CagA USING RECOMBINANT CagA ANTIGEN Microtitre wells were coated with 1 µg/well orv220 antigen fragment of CagA (OraVax enzyme linked immunosorbent assay (ELISA), OraVax Inc) in 100 µl/well carbonatebicarbonate buVer (100 mM, pH 9.6), overnight at 4°C. After washing and blocking with 200 µl/well 2.5% non-fat dried milk (NFDM) in phosphate buVered saline (PBS)-Tween (one hour, 37°C), serum samples diluted 1 in 100 in 100 µl/well NFDM/PBS-Tween were incubated at 37°C for one hour.
The second antibody, a goat antihuman IgG alkaline phosphatase conjugate, was then added at a dilution of 1:1000 at 37°C for one hour. After incubation with alkaline phosphatase substrate solution at 1 µg/ml in diethylamine-MgCl 2 buVer at room temperature for 20 minutes, the optical density was read at 405 nm. A standard curve of high titre positive and control serum samples was included on each plate. Results were expressed in ELISA units (0-100) determined from the standard curve. The cutoV was determined as 5.0 ELISA units. It was calculated as the mean plus 3 SD of the results obtained from 30 patients negative for H pylori (culture, histology, and urea breath test negative).
IMMUNOBLOTTING ASSAY FOR CagA AND VacA Chiron recombinant immunoblot H pylori immunoassay (Chiron-RIBA, Chiron Corporation, Emeryville, California, USA) consisted of two diVerent strips; one with a H pylori lysate (membrane derived antigens) and the other with the pathogenicity markers of this bacterium including VacA, CagA, and urease.
Membrane strips were incubated with 1:50 dilution of sera on a shaker for 4 to 4.5 hours at room temperature. After incubation, unbound serum components were removed by washing and aspiration. After washing, peroxidase labelled goat antihuman IgG conjugate was added to each strip and incubated for 9 to 11 minutes at room temperature. Substrate solution (hydrogen peroxide and 4-choro-1-naphthol) was added to each strip and agitated for 15 to 20 minutes at room temperature, after which the strips were washed twice with deionised water, dried, and mounted on nonabsorbent paper. Serum positive and negative controls were included with each assay. Two levels of human IgG (level I, low control; level II, high control) were included on each strip as internal controls. H pylori reactivity was determined by comparing the intensity of the human IgG (level I and level II) internal control bands on each strip. The identity of the antigen bands was scored in relation to the intensities of the internal IgG controls as follows: score −, intensity of band is absent; ±, less than intensity of the level I IgG control band; 1+, equal to intensity of the level I IgG control band; 2+, greater than intensity of the level I IgG control band and less than intensity of the level II IgG control band; 3+, equal to intensity of the level II IgG control band; 4+, greater than intensity of the level II IgG control band.
A cutoV for seropositivity was defined as comparing + and ± data obtained from 30 H pylori negative controls. As a result, ± data are regarded as positive for CagA antibody and negative for H pylori status and anti-VacA antibody.
Results are given as odds ratios (OR) and 95% confidence intervals (CI). 
Results
Seventy
VIRULENCE FACTORS AND GASTRIC CANCER
The presence of IgG antibody to CagA was similar in gastric cancer and control subjects using both the OraVax ELISA and the Chiron RIBA (83.3% v 81.1% with OraVax ELISA, 73.3% v 71.1% with Chiron immunoblots, for gastric cancer v H pylori positive controls, respectively) (p > 0.9; tables 2 and 3). The results were concordant in 86% (both positive or both negative in 64 and 13, respectively, among the cancer cases). The results with the two CagA antibody tests were discordant in 14%, with the OraVax ELISA yielding the higher estimate (OraVax+/Chiron− in 11 and OraVax−/Chiron+ in two). Nevertheless, the conclusions of the study were unchanged, irrespective of which CagA antigen was used.
VacA IgG antibody was positive in 82.2% of gastric cancers and 81.1% of controls (table 4) . There were no significant diVerences in histological classification, clinical stage, or location of the tumour and CagA or VacA status.
Discussion
This study confirmed that H pylori infection is associated with an increased risk of gastric cancer. [24] [25] [26] [27] We found a significant association between H pylori infection and intestinal type, distal type, early gastric cancer, and age < 55 years. H pylori infection is expected to have a strong relation to intestinal type gastric cancer, as chronic atrophic gastritis was recognised as a risk factor for gastric cancer for decades before the identification of H pylori as a cause of gastritis. 28 29 It is currently thought that H pylori infection has an indirect relation to gastric cancer and is largely responsible for the development of atrophic gastritis and the precursor lesion, intestinal metaplasia. 30 In Japan, the prevalence of atrophic gastritis is extremely high, with a 90% incidence in people over 60 years age. 31 There are only a few studies of the relation between H pylori and both early gastric cancer and advanced gastric cancer. 24 26 32 Our results are in agreement with those of Asaka et al, 24 who reported that H pylori IgG antibody titres were significantly higher in early cancer than in advanced cancer. The lower frequency of high titre IgG antibody in advanced cancer may be the result of a decrease in antibody titre, because of the increasing extent of intestinal metaplasia associated with transition from the intestinal type of early gastric cancer to advanced cancer, such that the local environment is no longer ideal for growth of H pylori. 24 33 34 There are many reports using recombinant CagA proteins used in this study, 9 10 18 19 35 but no studies comparing them. This study suggests that numerical results from studies using diVerent antigens and diVerent protocols may not be comparable. Epidemiology studies by Blaser et al 9 and Parsonnet et al 10 used the OraVax antigen, whereas the Eurogast Study Group 35 used IRIS antigen, which is also used in the Chiron test. It is not clear which, or if either, antigen provides the better assessment of the prevalence of infection with H pylori that contain the cag pathogenicity island. Overall, the conclusions of this study were the same (that is, that there was no relation between CagA antibody status and gastric cancer), irrespective of which antigen was used. Nevertheless, the proportion with positive tests diVered, with the OraVax ELISA yielding the higher estimate. The reason for the diVerence is unclear. It is possible that the ELISA may detect conformational and linear epitopes whereas the immunoblot is likely to detect only 18 19 It appears unlikely that diVerences in the test used were responsible for the diVerence in results they obtained.
Rudi et al reported that VacA antibody was associated with an increased risk of gastric cancer (OR = 1.74, 95% CI 1.08 to 2.78). 11 However, there was no relation between the VacA and gastric cancer in this study. The two studies used diVerent procedures and evaluated patients from diVerent countries. Whether the diVerences are procedural or geographical will require additional investigation.
